23. Anal Cancer - The GEC-ESTRO Handbook of Brachytherapy

Anal Cancer

14

THE GEC ESTROHANDBOOKOF BRACHYTHERAPY | Part II Clinical Practice Version 1 - 01/03/2023

15. REFERENCES

21. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012 Dec 10;30(35):4344–51. 22. Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiotherapy and Oncology. 2014 Jun;111(3):330–9. 23. Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, et al. Elective Clinical Target Volumes for Conformal Therapy in Anorectal Cancer: A Radiation Therapy Oncology Group Consensus Panel Contouring Atlas. International Journal of Radiation Oncology*Biology*Physics. 2009 Jul;74(3):824–30. 24. Frakulli R, Buwenge M, Cammelli S, Macchia G, Farina E, Arcelli A, et al. Brachytherapy boost after chemoradiation in anal cancer: a systematic review. jcb. 2018;10(3):246–53. 25. Hannoun-Levi JM, Ortholan C, Resbeut M, Teissier E, Ronchin P, Cowen D, et al. High-Dose Split-Course Radiation Therapy for Anal Cancer: Outcome Analysis Regarding the Boost Strategy (CORS-03 Study). International Journal of Radiation Oncology*Biology*Physics. 2011 Jul;80(3):712–20. 26. Moureau-Zabotto L, Ortholan C, Hannoun-Levi JM, Teissier E, CowenD, Salem N, et al. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study). Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):e135-142. 27. Cordoba A, Escande A, Leroy T, Mirabel X, Coche-Dequéant B, Lartigau E. Low-dose-rate interstitial brachytherapy boost for the treatment of anal canal cancers. Brachytherapy. 2017 Feb;16(1):230–5. 28. Oblak I, Petric P, Anderluh F, Velenik V, Fras PA. Long term outcome after combinedmodality treatment for anal cancer. Radiol Oncol. 2012 Jun;46(2):145– 52. 29. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Houry S, Gallot D, et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1259–73. 30. Weber DC, Kurtz JM, Allal AS. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675–80. 31. Peiffert D, Tournier-Rangeard L, Gérard JP, Lemanski C, François E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012 Jun 1;30(16):1941–8. 32. Lestrade L, De Bari B, Pommier P, Montbarbon X, Lavergne E, Ardiet JM, et al. Role of brachytherapy in the treatment of cancers of the anal canal. Long-term follow-up and multivariate analysis of a large monocentric retrospective series. Strahlenther Onkol. 2014 Jun;190(6):546–54. 33. Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M, Blomqvist C. Chemoradiotherapy of anal cancer is feasible in elderly patients: treatment results of mitomycin-5-FU combined with radiotherapy at Helsinki University Central Hospital 1992-2003. Acta Oncol. 2006;45(6):736–42. 34. Pierquin B, Dutreix A, Paine CH, Chassagne D, Marinello G, Ash D. The Paris system in interstitial radiation therapy. Acta Radiol Oncol Radiat Phys Biol. 1978;17(1):33–48. 35. Doniec JM, Schniewind B, Kovács G, Kahlke V, Loehnert M, Kremer B. Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy. Surg Endosc. 2006 Apr;20(4):673–8. 36. Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010 Mar;102(7):1123–8. 37. Arcelli A, Buwenge M, Macchia G, Cammelli S, Deodato F, Cilla S, et al. Long- term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis. J Contemp Brachytherapy. 2019 Feb;11(1):21–7. 38. Gryc T, Ott O, Putz F, Knippen S, Raptis D, Fietkau R, et al. Interstitial brachytherapy as a boost to patients with anal carcinoma and poor response to chemoradiation: Single-institution long-term results. Brachytherapy. 2016 Nov;15(6):865–72.

1. Petric P, Al-Hammadi N, Spindler KLG, Lindegaard JC. Anal cancer brachytherapy: From radon seeds to interstitial Papillon technique in a century. What does the future hold? Radiotherapy and Oncology. 2022 Apr;169:25–34. 2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7–33. 3. RousseauDL,Thomas CR, Petrelli NJ, KahlenbergMS. Squamous cell carcinoma of the anal canal. Surg Oncol. 2005 Nov;14(3):121–32. 4. Fléjou JF. An update on anal neoplasia. Histopathology. 2015 Jan;66(1):147–60. 5. Hoff PM, Coudry R, Moniz CMV. Pathology of Anal Cancer. Surg Oncol Clin N Am. 2017 Jan;26(1):57–71. 6. Tepper JE, Foote RL, Michalski J, editors. Gunderson & tepper’s clinical radiation oncology. 5th ed. Philadelphia: Elsevier; 2020. 7. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. JCO. 1997 May;15(5):2040–9. 8. Pommier P, Mirabel X, Hannoun-Lévi JM, Malet C, Gérard JP, Peiffert D. [Brachytherapy for anal cancers]. Cancer Radiother. 2013 Apr;17(2):143–50. 9. Peiffert D, Baumann AS, Serre AA, Vendrely V, Rouard N, Faivre JC, et al. [Anal canal cancer: In the era of intensity-modulated radiotherapy, outstanding issues]. Cancer Radiother. 2018 Oct;22(6–7):509–14. 10. Hester R, Advani S, Rashid A, Holliday E, Messick C, Das P, et al. CEA as a blood-based biomarker in anal cancer. Oncotarget. 2021May 25;12(11):1037–45. 11. Mahmud A, Poon R, Jonker D. PET imaging in anal canal cancer: a systematic review and meta-analysis. BJR. 2017 Dec;90(1080):20170370. 12. Sekhar H, Zwahlen M, Trelle S, Malcomson L, Kochhar R, Saunders MP, et al. Nodal stage migration and prognosis in anal cancer: a systematic review, meta- regression, and simulation study.The Lancet Oncology. 2017Oct;18(10):1348–59. 13. Jones M, Hruby G, SolomonM, Rutherford N, Martin J. The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis. Ann Surg Oncol. 2015 Oct;22(11):3574–81. 14. Mohammadkhani Shali S, Schmitt V, Behrendt FF,Winz OH, Heinzel A, Mottaghy FM, et al. Metabolic tumour volume of anal carcinoma on 18FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. European Journal of Radiology. 2016 Aug;85(8):1390–4. 15. Peterson CY, Weiser MR, Paty PB, Guillem JG, Nash GM, Garcia-Aguilar J, et al. Does Endoscopic Ultrasound Improve Detection of Locally Recurrent Anal Squamous-Cell Cancer? Diseases of the Colon &Rectum. 2015 Feb;58(2):193–8. 16. Ortholan C, Ramaioli A, Peiffert D, Lusinchi A, Romestaing P, Chauveinc L, et al. Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479–85. 17. Peiffert D. [Anal channel cancer: customization of dose, volume and breaching]. Cancer Radiother. 2019 Oct;23(6–7):773–7. 18. Badakhshi H, Budach V, Wust P, Graf R. Anal carcinoma: surgery does not influence prognosis when performed prior to concurrent radiochemotherapy. Anticancer Res. 2013 Sep;33(9):4111–5. 19. Ajani JA. Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial. JAMA. 2008 Apr 23;299(16):1914. 20. James RD, Glynne-Jones R, Meadows HM, CunninghamD, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial. The Lancet Oncology. 2013 May;14(6):516–24.